8.00 am Check In & Morning Coffee
8:50 am Chair’s Opening Remarks
Showcasing State-of-the-Art Peptide-Based Therapeutic Delivery Technologies to Accelerate Peptide Drugs Towards Patients
9:00 am Bio-Inspired Oral Drug Delivery Platforms for Biological Therapeutics
Synopsis
- Designing cutting-edge robotic devices for targeted peptide drug delivery
- Discussing underlying mechanisms of oral administration through the GI tissue to maximize the bioavailability
- Improving peptide bioavailability, increasing absorption and enabling high- dose peptide delivery
9:30 am Long-Acting Nanoformulation for the Delivery of Fusion Inhibitor Peptide & Small Molecule
Synopsis
- Considerations of physicochemical properties of the drugs and peptide for designing a long-acting combination drug delivery platform
- Unveiling how the site of injection/administration drives the pharmacokinetics of longacting formulations
- Showcasing how the drug delivery strategy is predetermined based on the immune cell target
10:00 am Peptide Modification for Targeted Delivery
Synopsis
- Selecting appropriate peptides for targeted delivery
- Ensuring bioconjugation efficiency
- Investigating the stability of peptides in the blood stream
10:30 am Morning Refreshments, Networking Break & Poster Session
11:30 am A Novel Safe & Re-Dosable Peptide-Based Nanoparticle Platform for Targeted Delivery
Synopsis
- Designing and using AI-driven optimization of a peptide-vector for cell membrane selectivity and cellular uptake
- Defining safety and characterization of peptide-based nanoparticles for extrahepatic delivery of different payloads including peptide, protein and RNA
- Applying a peptide-based nanoparticle platform for systemic targeted delivery of therapeutic mRNA: T cell engineering and tumor selectivity
12:00 pm Microsphere Delivery Systems for Controlling the Release of Proteins & Peptides
Synopsis
- Examining how microspheres are developed
- Revealing various types of microspheres
- Controlling peptide drug product release and maintaining stability
12.30 pm Lunch & Networking Break
Pushing the Limits of Peptide Formulation Through Different Modes of Administration to Maximize Pan-Disease Applications
1:30 pm Harnessing Polymeric Nanoparticle Technologies for Intradermal Peptide Delivery
Synopsis
- Applying nanoparticle delivery of peptides in atopic dermatitis with a polymer with antistaphylococcal activity that does not disturb dermal cell membranes
- Sharing skin biopsy data that demonstrates how leveraging nanoparticle transfection agents to deliver peptides into dermal cells is faster and more effective, compared to topical steroids
- Enabling microdose peptide delivery and discussing the safety aspect of topical peptide applications
2:00 pm Enhancing Bioavailability of Peptide Drugs for Nasal Delivery
Synopsis
- Providing an overview of the opportunities and challenges of nasal drug delivery
- Overcoming some of the key challenges to nasal delivery through the use of absorption enhancers
- Discussing considerations of formulation aspects of nasal drug development
- Making considerations for translational aspects of nasal drug product development
- Demonstrating human and animal data examples of improvements in bioavailability for small molecules and nose to brain delivery for peptides using an absorption enhancer
2:30 pm Next-Generation Nasal & Inhalation Delivery of Peptides: Enhancing Stability & Barrier Penetration
Synopsis
- Overcoming challenges of localized inhalation and nasal delivery to the lungs and to the brain, respectively
- Highlighting next-generation encapsulation techniques to stabilize peptides for delivery without any chemical conjugation
- Crossing mucosal, epithelial and cellular barriers
3.00 pm Afternoon Networking Break
Harnessing Cross-Learnings From GLP-1 Targeted Therapies & Peptide-Based Drugs in Clinical Stages of Development to Optimize Target Product Profiles
3:30 pm Showcasing Risperidone as an Oral Weekly, as Opposed to Oral Daily Capsule for the Treatment of Schizophrenia
Synopsis
Details to be released
4:00 pm Considerations for Development & Commercialization of Peptide Products
Synopsis
- Managing the evolution of dosage forms from early to late-stage development
- Understanding the implications of chemical and physical stability throughout the development program
- Evolving a target product profile (TPP) through the development program
- Using a novel formulation platform to achieve better TPP